Head and neck cancers are not curable yet but survival and local control has been increased due to concurrent treatment approach. Study was conducted to assess the role of concurrent Gemcitabine (2'2' Difluro Deoxycytidine) along with radiotherapy in treatment of Head and Neck cancers and to assess local control as well as disease free survival achieved due to chemoradiation. 100 patients were enrolled in this study, 50 patients received Radiotherapy (Group A- Control group) alone and 50 patients received Concurrent Chemoradiotherapy (Group B- Study group). Patients in study group received Gemcitabine 200mg/m2 on weekly basis for 5-7 cycles over 30 mins. Radiation delivered after 2 hours of IV infusion. Conventional radiotherapy was given in dose ranging from 66-70Gy in 33-37# for 6-7weeks. In this study, Grade 3 mucositis and Grade 2 pharyngeal toxicity were common i.e, 56% and 54% respectively in study group and 30% and 38% respectively in control group. Hematological toxicity i.e., Grade 1 leucopenia was seen in 28%. Even though the toxicities were high in study group compare to control group but they were tolerable and acceptable. The response was better in concurrent group than radiotherapy alone (Control group) CR 52% vs 40%, PR 34% vs 36% and SD 14% vs 24%. Concurrent use of gemcitabine and radiotherapy is a effective modality in treatment of head and neck cancers with acceptable toxicity. Improved local control shows that Gemcitabine acts as a sensitizers and has synergistic action along with radiotherapy. [Int J Res Med Sci 2013; 1(4.000): 392-396

No abstract

Introduction: Ovarian lesions are commonly encountered and are complex in gynecological practice which can be either benign, borderline or malignant which constitutes a high fatality rate and it cannot be categorized clinico -radiologically. Definite diagnosis is of great importance for therapeutic and prognostic purposes. Histopathology gives accurate diagnosis in most of the cases. Aims: To study the histopathological pattern of ovarian lesions in different age group and also to analyse the associated clinical and radiological findings. Methods: A retrospective study conducted on 69 cases of ovarian lesions reported from June 2016-May 2019 in pathology department at Sri Manakula Vinayagar medical college and hospital, Puducherry Results: Out of sixty nine ovarian lesions, 24 were non neoplastic and 45 were neoplastic lesions. Out of the neoplastic lesions 39 were benign and 6 were malignant. Among non-neoplastic lesions follicular cyst 12 was the most common lesion followed by endometriotic cysts 10. The majority of the cases were seen in the age group of 41-50 years. Conclusion: Most ovarian lesions were common in the age group 20-50 years. Neoplastic ovarian lesions are more common than non-neoplastic lesion.

No abstract

The natural repertory of the normal human immune system’s NK and T cells, as well as pharmacological elaborations, includes killing tumour cells. Aggressive human malignancies, on the other hand, are selected by the host immune system’s death of sensitive tumour cells and the survival of immune-resistant cancer cells. The capacity of these cells to evade “normal” immune killing actions could be a primary cause of malignancy progression, resulting in clonal growth, metastases, and patient death. The Ayurvedic idea of Vyadhikshamatwa, (Immunity) which re-engages the immune system to stage a counter-revolution, lays the path for a considerable clinical improvement in overall survival of patients with enhanced quality of life. Strategies like Rasayana Chikitsa can help to boost attempts to remove immune suppression in tumours by rousing dormant T-cell activity and restoring immune surveillance, especially when combined with chemotherapy and radiotherapy. The study uncovers aspects of cancer, immunotherapy, Ayurvedic aspects of Immunity and evidence of Immunotherapeutic properties of Rasayanas. Immunostimulatory immunotherapy, such as Rasayana Chikitsa, is the focus of this work which could show to be highly effective by restoring the patient’s inherent immune powers, opening up a new therapeutic front in the clinical arena of Cancer. Although the clinical studies are limited, the present study hope towards more approvals and wider usage of Rasayana Chikitsa in Cancer.